Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 26, 2026, 8:08 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: Placebo for MAD Clear all
Recruiting Early Phase 1 Interventional

VTP-1000 in Adults With Celiac Disease

NCT06310291
View directory record Official record
Conditions
Celiac Disease
Interventions
VTP-1000, Matched Placebo
Biological · Other
Lead sponsor
Barinthus Biotherapeutics
Industry
Eligibility
18 Years to 70 Years
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2026
U.S. locations
16
States / cities
Los Angeles, California • Colorado Springs, Colorado • Jacksonville, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jun 17, 2026 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study to Evaluate IMG-004 in Healthy Participants

NCT05349097
View directory record Official record
Conditions
Healthy Participants
Interventions
SAD IMG-004 30mg, SAD IMG-004 100mg, SAD IMG-004 200mg, SAD IMG-004 400mg, SAD IMG-004 600mg, SAD Placebo 30mg, SAD Placebo 100mg, SAD Placebo 200mg, SAD Placebo 400mg, SAD Placebo 600mg, MAD IMG-004 50mg, MAD Placebo 50mg, MAD IMG-004 150mg, MAD Placebo 150mg, MAD IMG-004 300mg, MAD Placebo 300mg, FE IMG-004 150mg
Drug
Lead sponsor
Inmagene LLC
Industry
Eligibility
18 Years to 60 Years
Enrollment
72 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Daytona Beach, Florida
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study Evaluating the Safety, Pharmacokinetics, and Pharmacodynamics, of VX-993

NCT06226454
View directory record Official record
Conditions
Pain
Interventions
VX-993, Placebo
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
39 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jul 11, 2024 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Phase 1 Single Ascending Dose and Multiple Ascending Dose Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of VBP15 in Healthy Adult Subjects

NCT02415439
View directory record Official record
Conditions
Healthy
Interventions
VBP15, Placebo
Drug
Lead sponsor
ReveraGen BioPharma, Inc.
Industry
Eligibility
18 Years to 65 Years
Enrollment
86 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2016
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2017 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase 1 Study of TDM-180935 Following Topical Administration in Healthy Male Subjects

NCT05525468
View directory record Official record
Conditions
Healthy
Interventions
TDM-180935, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
58 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Fair Lawn, New Jersey
Source: ClinicalTrials.gov public record
Updated Nov 17, 2023 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers Results available

A Study to Assess the Safety, Tolerability, and Pharmacokinetics of Ascending, Subcutaneous, Single and Multiple Doses of SHP681 (Glucagon-like Peptide-2 [GLP-2] Analog-Fc Fusion) in Healthy Adult Participants

NCT03859323
View directory record Official record
Conditions
Healthy Volunteers
Interventions
SHP681, Placebo
Drug · Other
Lead sponsor
Shire
Industry
Eligibility
18 Years to 50 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
Knoxville, Tennessee
Source: ClinicalTrials.gov public record
Updated Feb 24, 2021 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Changes in Metabolic Rate and Perceptual Indicators After Acute Ingestion of Paraxanthine

NCT05811923
View directory record Official record
Conditions
Metabolic Syndrome, Caffeine
Interventions
Venous Blood Collection, Resting Metabolic Rate Determination, Mood State, Visual Analog Scales
Other
Lead sponsor
Lindenwood University
Other
Eligibility
18 Years to 39 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Saint Charles, Missouri
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 26, 2026, 8:08 AM EDT
Terminated Phase 1 Interventional Accepts healthy volunteers

SAD and MAD Study of FTX-101 in Healthy Male Subjects

NCT06617546
View directory record Official record
Conditions
Healthy Volunteers
Interventions
FTX-101, Placebo
Drug
Lead sponsor
Find Therapeutics
Industry
Eligibility
18 Years to 59 Years · Male only
Enrollment
49 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Jun 17, 2025 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Study of the Safety, Tolerability, and PK of MRX-8 Administered Intravenously to HVs in SAD and MAD Cohorts

NCT04649541
View directory record Official record
Conditions
Safety
Interventions
MRX-8, Placebo
Drug
Lead sponsor
MicuRx
Industry
Eligibility
18 Years to 55 Years
Enrollment
69 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Tempe, Arizona
Source: ClinicalTrials.gov public record
Updated Aug 23, 2023 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

First-In-Human Study of CU06-1004 Following Single and Multiple Ascending Doses in Healthy Volunteers

NCT04795037
View directory record Official record
Conditions
Diabetic Macular Edema
Interventions
CU06-1004, Single dose, CU06-1004, Multiple doses, Placebo
Drug
Lead sponsor
Curacle Co., Ltd.
Industry
Eligibility
19 Years to 55 Years
Enrollment
81 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Lincoln, Nebraska
Source: ClinicalTrials.gov public record
Updated Jul 20, 2022 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Phase I Study of Progerinin in Healthy Volunteers

NCT04512963
View directory record Official record
Conditions
Hutchinson-Gilford Progeria Syndrome, Werner Syndrome
Interventions
Progerinin, Placebo
Drug
Lead sponsor
PRG Science & Technology Co., Ltd.
Industry
Eligibility
18 Years to 45 Years
Enrollment
64 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Glendale, California
Source: ClinicalTrials.gov public record
Updated Sep 21, 2021 · Synced Sep 26, 2026, 8:08 AM EDT
Recruiting Phase 1 Interventional Accepts healthy volunteers

A Phase 1, First-in-human Study of VX-433

NCT07584434
View directory record Official record
Conditions
Narcolepsy Type 1 (NT1)
Interventions
VX-433, Placebo, Midazolam, Bupropion
Drug
Lead sponsor
Vertex Pharmaceuticals Incorporated
Industry
Eligibility
18 Years to 55 Years
Enrollment
118 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2027
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Jun 7, 2026 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study to Assess the Safety, Tolerability and Pharmacokinetics of AVI-7288 in Healthy Adult Volunteers

NCT01566877
View directory record Official record
Conditions
Marburg Hemorrhagic Fever
Interventions
AVI-7288, Placebo
Drug · Other
Lead sponsor
Sarepta Therapeutics, Inc.
Industry
Eligibility
18 Years to 50 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2014
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 6, 2014 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP 305 in Healthy Subjects and Subjects With Presumptive NAFLD

NCT02918929
View directory record Official record
Conditions
Presumptive NAFLD
Interventions
EDP 305, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
146 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 20, 2017 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

SAD/MAD Safety and PK Study of QPX9003 (Novel Polymyxin) in Normal Healthy Volunteers

NCT04808414
View directory record Official record
Conditions
Bacterial Infections
Interventions
QPX9003 for IV Infusion, Placebo for IV infusion
Drug
Lead sponsor
Qpex Biopharma, Inc.
Industry
Eligibility
18 Years to 60 Years
Enrollment
104 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2022
U.S. locations
1
States / cities
Cypress, California
Source: ClinicalTrials.gov public record
Updated Oct 9, 2022 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Ascending Dose Pharmacokinetic (PK) and Absolute Bioavailability (BA)

NCT00983255
View directory record Official record
Conditions
Bacterial Infections
Interventions
TR-701 FA for injection, 200 mg/vial, TR-701 FA tablets
Drug
Lead sponsor
Trius Therapeutics LLC, a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Industry
Eligibility
18 Years to 50 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated May 18, 2016 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional

A Study Evaluating GS-9620 in Treatment Naive Subjects With Chronic Hepatitis C

NCT01591668
View directory record Official record
Conditions
Hepatitis C
Interventions
Single Ascending Dose Cohorts GS-9620, Multiple Ascending Dose Cohorts GS-9620
Drug
Lead sponsor
Gilead Sciences
Industry
Eligibility
18 Years to 65 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
10
States / cities
Little Rock, Arkansas • DeLand, Florida • Orlando, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Aug 12, 2013 · Synced Sep 26, 2026, 8:08 AM EDT
Recruiting Phase 1Phase 2 Interventional Accepts healthy volunteers

First-in-human Study of the Safety, Tolerability, Pharmacokinetics, and Food Effect of ACCG-2671

NCT07815678
View directory record Official record
Conditions
Obesity
Interventions
ACCG-2671, Placebo
Drug
Lead sponsor
Aconcagua Bio, Inc. a wholly owned subsidiary of Structure Therapeutics
Industry
Eligibility
25 Years to 75 Years
Enrollment
164 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2025 – 2027
U.S. locations
6
States / cities
Cypress, California • Lake Forest, California • Decatur, Georgia + 3 more
Source: ClinicalTrials.gov public record
Updated Sep 13, 2026 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Safety and Pharmacokinetics of SAD/MAD Oral Doses of SRP-3D (DA)

NCT05484414
View directory record Official record
Conditions
Pain
Interventions
SRP-3D (diethylamide), Placebo
Drug
Lead sponsor
South Rampart Pharma, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
50 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2023
U.S. locations
1
States / cities
Miami, Florida
Source: ClinicalTrials.gov public record
Updated Sep 9, 2026 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of EDP-938 in Healthy Subjects

NCT03384823
View directory record Official record
Conditions
RSV Infection
Interventions
EDP-938, Placebo
Drug
Lead sponsor
Enanta Pharmaceuticals, Inc
Industry
Eligibility
18 Years to 55 Years
Enrollment
90 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017 – 2018
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Oct 9, 2018 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Study of TDM-105795 in Male Subjects With Androgenetic Alopecia (AGA)

NCT05244980
View directory record Official record
Conditions
Alopecia, Androgenetic
Interventions
TDM-105795, Placebo
Drug
Lead sponsor
Technoderma Medicines Inc.
Industry
Eligibility
18 Years to 55 Years · Male only
Enrollment
32 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
2
States / cities
San Diego, California • College Station, Texas
Source: ClinicalTrials.gov public record
Updated Mar 13, 2023 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Early Phase 1 Interventional Accepts healthy volunteers

FTIH of ECC4703 in Healthy Volunteers

NCT05552274
View directory record Official record
Conditions
Non-alcoholic Steatohepatitis (NASH)
Interventions
ECC4703, Placebo
Drug
Lead sponsor
Eccogene
Industry
Eligibility
18 Years to 65 Years
Enrollment
75 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Las Vegas, Nevada
Source: ClinicalTrials.gov public record
Updated Jul 4, 2024 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MAD Study to Evaluate the Safety, Tolerability and Pharmacokinetics of Intravenous Zidebactam in Healthy Adults

NCT02674347
View directory record Official record
Conditions
Healthy Subjects
Interventions
3 g or 6 g Zidebactam, Placebo
Drug
Lead sponsor
Wockhardt
Industry
Eligibility
18 Years to 55 Years
Enrollment
21 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016
U.S. locations
1
States / cities
Overland Park, Kansas
Source: ClinicalTrials.gov public record
Updated Sep 29, 2025 · Synced Sep 26, 2026, 8:08 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

MAD Study of IA-14069

NCT05533372
View directory record Official record
Conditions
Healthy, Rheumatoid Arthritis
Interventions
IA-14069, Placebo, Methotrexate
Drug
Lead sponsor
ILAb Co., Ltd.
Industry
Eligibility
18 Years to 70 Years
Enrollment
78 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Lenexa, Kansas
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Sep 26, 2026, 8:08 AM EDT